Skip to main content
. 2017 Sep 7;36(12):2673–2682. doi: 10.1007/s10067-017-3804-5

Table 4.

Demographic, clinical, and laboratory characteristics of RA patients with and without renal dysfunction based on BSA-indexed eGFR values

With renal dysfunctiona (n = 355) Without renal dysfunctiona (n = 1553) p valueb
Age, years, mean (SD) 73.1 (9.6) 61.0 (12.7) < 0.001
 ≥ 65 years, patient number (%) 294 (82.8) 652 (42.0) < 0.001
Male/female 60/295 290/1263 0.49
RA duration, years, mean (SD) 12.7 (11.2) 10.3 (9.0) < 0.001
 ≤ 3 years, patient number (%) 55 (15.5) 345 (22.2) 0.005
Anti-CCP (+), patient number (%) 280 (78.9) 1206 (77.7) 0.67
Stage III/IV, patient number (%) 187 (52.7) 724 (46.6) 0.045
CDAI, mean (SD) 6.3 (6.7) 6.2 (6.6) 0.84
HAQ, mean (SD) 0.59 (0.79) 0.38 (0.60) < 0.001
 ≥ 1.0, patient number (%) 87 (24.5) 244 (15.7) < 0.001
 < 0.25, patient number (%) 157 (44.2) 514 (33.1) < 0.001
Serum CRP, mg/dl, mean (SD) 0.47 (1.31) 0.33 (0.81) 0.014
BMI, kg/m2, mean (SD) 22.7 (3.4) 22.5 (3.7) 0.31
 > 25, patient number (%) 79 (22.3) 328 (21.1) 0.67
 < 18.5, patient number (%) 29 (8.2) 167 (10.8) 0.18
Hypertension, patient number (%) 216 (60.1) 408 (26.3) < 0.001
NIDDM, patient number (%) 61 (17.2) 133 (8.6) < 0.001
Serum LDL-C, mg/dl, mean (SD) 112.4 (31.3) 111.2 (28.2) 0.50
 ≥ 140 mg/dl, patient number (%) 61 (17.4) 213 (13.6) 0.094
Current/ex-smokers, number (%) 64 (18.0) 338 (21.8) 0.13
Use of biologics, patient number (%) 135 (38.0) 506 (32.6) 0.054
MTX use, patient number (%) 141 (39.4) 844 (54.3) < 0.001
 Dose, mg/week, mean (SD) 6.7 (3.0) 8.4 (3.6) < 0.001
 Cumulative dose, g, median (IQR) 2.7 (1.3–4.3) 2.8 (1.2–4.7) 0.22
NSAID use, patient number (%) 91 (25.6) 397 (25.6) 1.00
 ASAS-NSAID score, mean (SD) 49.8 (19.9) 48.2 (21.2) 0.50
 Concurrent steroids, number (%) 54 (15.2) 183 (11.8) 0.094
Steroid use, patient number (%) 127 (35.8) 458 (29.5) 0.022
 Dose, mg/day, mean (SD) 3.0 (1.9) 2.9 (2.1) 0.80
 Cumulative dose, g, median (IQR) 5.0 (1.5–14.6) 3.2 (0.8–9.5) < 0.001

RA rheumatoid arthritis, eGFR estimated glomerular filtration rate, anti-CCP anti-citrullinated peptide antibodies, CDAI clinical disease activity index, HAQ health assessment questionnaire, CRP C-reactive protein, BMI body mass index, NIDDM non-insulin-dependent diabetes mellitus, LDL-C low-density lipoprotein cholesterol, MTX methotrexate, NSAIDs nonsteroidal anti-inflammatory drugs, ASAS Assessment of Spondyloarthritis International Society, SD standard deviation, IQR interquartile range

aDefined as a BSA-indexed eGFR <60 ml/min/1.73 m2. Average values of two measurements of eGFR taken over a 3-month interval were used

bComparison between RA patients with renal dysfunction and those without